New cocktail of drugs and procedure aims to stop liver cancer in its tracks
NCT ID NCT07150377
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial is testing a combination of two immunotherapy drugs (iparomlimab and tuvonralimab), a targeted therapy (lenvatinib), and a procedure that blocks the tumor's blood supply (TACE) in 41 people with advanced liver cancer. The goal is to see if this mix can keep the cancer from growing longer than current treatments. Participants will be divided into two groups: those who have never had systemic therapy and those who have had prior treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
iparomlimab, tuvonralimab, lenvatinib, and transarterial chemoembolization (TACE)
What this could lead to
If successful, this combination could offer a new treatment option to slow or shrink advanced liver cancer, potentially extending life without the disease getting worse.
What could go wrong
This is a small, early-phase trial with no control group, so results may not be definitive. The combination of drugs and TACE may cause significant side effects, and the benefit over standard care is unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••